Skip to main content
Premium Trial:

Request an Annual Quote

Affy Expands GeneChip Deal with GlaxoSmithKline

NEW YORK, Sept 10 – Affymetrix said Monday that it had expanded its agreement to provide GlaxoSmithKline with its GeneChip technology. 

Under the terms of the deal, Glaxo’s research centers will be able to receive customized GeneChip arrays in smaller format sizes, providing them with lower cost arrays for high-throughput studies.

The deal reflects a new Affymetrix effort to offer specialized arrays at reduced prices.

"GSK's broader adoption of Affymetrix' GeneChip technology validates our belief that the market is shifting towards pre-synthesized oligonucleotide arrays," Susan Siegel, president of Affymetrix, said in a statement.

"By leveraging our unique and flexible wafer-based manufacturing process, we are able to provide chips at the lowest cost per datapoint in the industry with content intended to meet specific needs," Siegel added. 

Financial terms of the deal were not disclosed. 

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.